Your CDMO partner of choice for Viral Vector Manufacturing

Time is of the essence in the clinical development of new therapies, and manufacturing is often a real bottleneck for cell and gene therapy producers. At Yposkesi, we have one of the largest AAV (Adeno-Associated Virus) and lentiviral vector development and manufacturing capacities in Europe. Our growing cGMP facilities, dedicated manpower, and expertise allow us to easily accommodate new projects and meet the timeline and budget for your breaking ground in therapeutic treatments. Yposkesi is the CDMO partner of choice for viral vector manufacturing.

Yposkesi is a trusted CDMO partner with both technical expertise and a long-term commitment to quality, with more than 30 years of experience.
Our services encompass bioprocess development, cGMP manufacturing of AAV and lentiviral vectors, Fill & Finish, QC, QA, CMC, and regulatory support. We aim to establish an open and trustworthy relationship with you. With the ultimate goal of reducing time-to-market and ensuring an uninterrupted supply of viral vectors, we are heading to your clinical trials and commercial manufacturing.

There is a significant industrial challenge to overcome the manufacturing costs of cell and gene therapy products.
As a leading CDMO, Yposkesi is at the forefront of designing new techniques that improve process robustness and scalability: increasing the productivity of our development and manufacturing processes. We have a highly skilled and dedicated innovation team focused on your evolving needs and requirements for a committed, sustainable, and competitive AAV and lentiviral vector supply.